George Bickerstaff

George Bickerstaff has had a long and successful career in the pharmaceutical and biotech industries. George is currently a director at Innoviva, and has previously served on the boards of Sio Gene Therapies, RoosterBio Inc., INOVIO Pharmaceuticals, Inc., and ARIAD Pharmaceuticals, Inc. George has also been a chairperson for Cardax, Inc. and Cyclica.

George has played an instrumental role in the development and commercialization of many groundbreaking therapies and treatments. George has helped to transform the lives of patients with neurodegenerative diseases, cancer, and infectious diseases. Their work has made a significant impact on the medical field, and they continue to be a leader in the industry.

George Bickerstaff attended Rutgers University for their undergraduate degrees, receiving a Bachelor of Science in Industrial Engineering and a Bachelor of Arts in Business Administration. George then attended Harvard Business School for continuing executive education, sponsored by Novartis. George Bickerstaff is also certified by the Financial Industry Regulatory Authority in FINRA Series 63, 7 and 24.